Point-counterpoint: Piperacillin-tazobactam should be used to treat infections with extended-spectrum-beta-lactamase-positive organisms

Journal of Clinical Microbiology

Volumn 56, Issue 3, 2018, Pages

  Schuetz, Audrey N ^a   Reyes, Sergio ^b   Tamma, Pranita D ^c  

^a Mayo Clinic College of Medicine   (United States)

^b CENTRO INTERNACIONAL DE ENTRENAMIENTO E INVESTIGACIONES MÉDICAS CIDEIM   (Colombia)

^c JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CARBAPENEM; MEROPENEM; PIPERACILLIN PLUS TAZOBACTAM; ANTIINFECTIVE AGENT; BETA LACTAMASE INHIBITOR; CARBAPENEM DERIVATIVE;

ABDOMINAL INFECTION; ARTICLE; BACTERIUM IDENTIFICATION; BILIARY TRACT INFECTION; BLOODSTREAM INFECTION; CLINICAL OUTCOME; DISEASE SEVERITY; DRUG EFFICACY; ENTEROBACTERIACEAE INFECTION; EXTENDED SPECTRUM BETA LACTAMASE PRODUCING ENTEROBACTERIACEAE; HUMAN; LABORATORY TEST; MEDICAL DECISION MAKING; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); TREATMENT INDICATION; URINARY TRACT INFECTION; BETA-LACTAM RESISTANCE; CLINICAL DECISION MAKING; DRUG EFFECT; ENZYMOLOGY; GENETICS; GRAM NEGATIVE BACTERIUM; GRAM NEGATIVE INFECTION; MICROBIAL SENSITIVITY TEST; PHARMACOLOGY;

ANTI-BACTERIAL AGENTS; BETA-LACTAM RESISTANCE; BETA-LACTAMASE INHIBITORS; CARBAPENEMS; CLINICAL DECISION-MAKING; GRAM-NEGATIVE BACTERIA; GRAM-NEGATIVE BACTERIAL INFECTIONS; HUMANS; MICROBIAL SENSITIVITY TESTS; PIPERACILLIN, TAZOBACTAM DRUG COMBINATION;

EID: 85042606161     PISSN: 00951137     EISSN: 1098660X     Source Type: Journal    
DOI: 10.1128/JCM.01917-17     Document Type: Article

References (33)

1. Collins VL, Marchaim D, Pogue JM, Moshos J, Bheemreddy S, Sunkara B, Shallal A, Chugh N, Eiseler S, Bhargava P, Blunden C, Lephart PR, Memon BI, Hayakawa K, Abreu-Lanfranco O, Chopra T, Munoz-Price LS, Carmeli Y, Kaye KS. 2012. Efficacy of ertapenem for treatment of bloodstream infections caused by extended-spectrum-lactamase-producing Enterobacteriaceae. Antimicrob Agents Chemother 56:2173–2177. https://doi.org/10.1128/AAC.05913-11.
2. Gavin PJ, Suseno MT, Thomson RB, Jr, Gaydos JM, Pierson CL, Halstead DC, Aslanzadeh J, Brecher S, Rotstein C, Brossette SE, Peterson LR. 2006. Clinical correlation of the CLSI susceptibility breakpoint for piperacillin tazobactam against extended-spectrum-beta-lactamase-producing Escherichia coli and Klebsiella species. Antimicrob Agents Chemothe 50:2244–2247. https://doi.org/10.1128/AAC.00381-05.
3. Trivedi M, Patel V, Soman R, Rodriguez C, Singhal T. 2012. The outcome of treating ESBL infections with carbapenems vs. non carbapenem antimicrobials. J Assoc Physicians India 60:28–30.
4. Seo YB, Lee J, Kim YK, Lee SS, Lee JA, Kim HY, Uh Y, Kim HS, Song W. 2017. Randomized controlled trial of piperacillin-tazobactam, cefepime and ertapenem for the treatment of urinary tract infection caused by extended-spectrum beta-lactamase-producing Escherichia coli. BMC Infect Dis 17:404. https://doi.org/10.1186/s12879-017-2502-x.
5. Clinical and Laboratory Standards Institute. 2017. Performance standards for antimicrobial susceptibility testing. Twenty-seventh informational supplement. M100-S27. CLSI, Wayne, PA.
6. Endimiani A, Luzzaro F, Brigante G, Perilli M, Lombardi G, Amicosante G, Rossolini GM, Toniolo A. 2005. Proteus mirabilis bloodstream infections: risk factors and treatment outcome related to the expression of extended-spectrum beta-lactamases. Antimicrob Agents Chemother 49: 2598–2605. https://doi.org/10.1128/AAC.49.7.2598-2605.2005.
7. Paterson DL, Ko WC, Von Gottberg A, Mohapatra S, Casellas JM, Goos-sens H, Mulazimoglu L, Trenholme G, Klugman KP, Bonomo RA, Rice LB, Wagener MM, McCormack JG, Yu VL. 2004. Antibiotic therapy for Klebsiella pneumoniae bacteremia: implications of production of extended-spectrum beta-lactamases. Clin Infect Dis 39:31–37. https://doi.org/10.1086/420816.
8. Tumbarello M, Sanguinetti M, Montuori E, Trecarichi EM, Posteraro B, Fiori B, Citton R, D’Inzeo T, Fadda G, Cauda R, Spanu T. 2007. Predictors of mortality in patients with bloodstream infections caused by extended-spectrum-beta-lactamase-producing Enterobacteriaceae: importance of inadequate initial antimicrobial treatment. Antimicrob Agents Chemother 51:1987–1994. https://doi.org/10.1128/AAC.01509-06.
9. Chaubey VP, Pitout JD, Dalton B, Ross T, Church DL, Gregson DB, Laupland KB. 2010. Clinical outcome of empiric antimicrobial therapy of bacteremia due to extended-spectrum beta-lactamase producing Escherichia coli and Klebsiella pneumoniae. BMC Res Notes 3:116. https://doi.org/10.1186/1756-0500-3-116.
10. Tamma PD, Han JH, Rock C, Harris AD, Lautenbach E, Hsu AJ, Avdic E, Cosgrove SE; Antibacterial Resistance Leadership group. 2015. Carbap-enem therapy is associated with improved survival compared with piperacillin-tazobactam for patients with extended-spectrum-lactamase bacteremia. Clin Infect Dis 60:1319–1325.
11. Rodríguez-Baño J, Navarro MD, Retamar P, Picón E, Pascual Á; Extended-Spectrum Beta-Lactamases–Red Española de Investigación en Patología Infecciosa/Grupo de Estudio de Infección Hospitalaria group. 2012. -Lactam/-lactam inhibitor combinations for the treatment of bacteremia due to extended-spectrum-lactamase-producing Escherichia coli: a post hoc analysis of prospective cohorts. Clin Infect Dis 54:167–174. https://doi.org/10.1093/cid/cir790.
12. Liakopoulos A, Mevius D, Ceccarelli D. 2016. A review of SHV extended-spectrum-lactamases: neglected yet ubiquitous. Front Microbiol 7:1374. https://doi.org/10.3389/fmicb.2016.01374.
13. CLSI. 2015. Verification of commercial microbial identification and antimicrobial susceptibility testing systems, 1st ed. CLSI guideline M52. Clinical and Laboratory Standards Institute, Wayne, PA.
14. Adler A, Katz DE, Marchaim D. 2016. The continuing plague of extended-spectrum B-lactamase-producing Enterobacteriaceae infections. Infect Dis Clin North Am 30:347–375. https://doi.org/10.1016/j.idc.2016.02.003.
15. Rodríguez-Baño J, Navarro MD, Retamar P, Picón E, Pascual Á; Extended-Spectrum Beta-Lactamases–Red Española de Investigación en Patología Infecciosa/Grupo de Estudio de Infección Hospitalaria Group. 2012. -Lactam/-lactam inhibitor combinations for the treatment of bacteremia due to extended-spectrum-lactamase-producing Escherichia coli: a post hoc analysis of prospective cohorts. Clin Infect Dis 54: 167–174. https://doi.org/10.1093/cid/cir790.
16. Gutiérrez-Gutiérrez B, Pérez-Galera S, Salamanca E, de Cueto M, Calbo E, Almirante B, Viale P, Oliver A, Pintado V, Gasch O, Martínez-Martínez L, Pitout J, Akova M, Peña C, Molina J, Hernández A, Venditti M, Prim N, Origüen J, Bou G, Tacconelli E, Tumbarello M, Hamprecht A, Giamarellou H, Almela M, Pérez F, Schwaber MJ, Bermejo J, Lowman W, Hsueh PR, Mora-Rillo M, Natera C, Souli M, Bonomo RA, Carmeli Y, Paterson DL, Pascual A, Rodríguez-Baño J. 2016. A multinational, preregistered cohort study of B-lactam/B-lactamase inhibitor combinations for treatment of bloodstream infections due to extended-spectrum B-lactamase-producing Enterobacteriaceae. Antimicrob Agents Chemother 60: 4159–4169. https://doi.org/10.1128/AAC.00365-16.
17. Ng TM, Khong WX, Harris PN, De PP, Chow A, Tambyah PA, Lye DC. 2016. Empiric piperacillin-tazobactam versus carbapenems in the treatment of bacteremia due to extended-spectrum beta-lactamase-producing Enterobacteriaceae. PLoS One 11:e0153696. https://doi.org/10.1371/journal.pone.0153696.
18. Gudiol C, Royo-Cebrecos C, Abdala E, Akova M, Álvarez R, Maestro-de la Calle G, Cano A, Cervera C, Clemente WT, Martín-Dávila P, Freifeld A, Gómez L, Gottlieb T, Gurguí M, Herrera F, Manzur A, Maschmeyer G, Meije Y, Montejo M, Peghin M, Rodríguez-Baño J, Ruiz-Camps I, Sukiennik TC, Tebe C, Carratalà J; BICAR Study Group. 2017. Efficacy of -lactam/-lactamase inhibitor combinations for the treatment of bloodstream infection due to extended-spectrum-lactamase-producing Enterobacteriaceae in hematological patients with neutro-penia. Antimicrob Agents Chemother 61:e00164-17. https://doi.org/10.1128/AAC.00164-17.
19. Thomson KS, Moland ES 2001. Cefepime, piperacillin-tazobactam, and the inoculum effect in tests with extended-spectrum-lactamase-producing Enterobacteriaceae. Antimicrob Agents Chemother 45: 3548–3554. https://doi.org/10.1128/AAC.45.12.3548-3554.2001.
20. Burgess DS, Hall RG, II. 2004. In vitro killing of parenteral beta-lactams against standard and high inocula of extended-spectrum-lactamase and non-ESBL producing Klebsiella pneumoniae. Diagn Microbiol Infect Dis 49:41–46. https://doi.org/10.1016/j.diagmicrobio.2003.11.007.
21. Docobo-Pérez F, López-Cerero L, López-Rojas R, Egea P, Domínguez-Herrera J, Rodríguez-Baño J, Pascual A, Pachón J. 2013. Inoculum effect on the efficacies of amoxicillin-clavulanate, piperacillin-tazobactam, and imipenem against extended-spectrum-lactamase (ESBL)-producing and non-ESBL-producing Escherichia coli in an experimental murine sepsis model. Antimicrob Agents Chemother 57:2109–2113. https://doi.org/10.1128/AAC.02190-12.
22. Harada Y, Morinaga Y, Kaku N, Nakamura S, Uno N, Hasegawa H, Izumikawa K, Kohno S, Yanagihara K. 2014. In vitro and in vivo activities of piperacillin-tazobactam and meropenem at different inoculum sizes of ESBL-producing Klebsiella pneumoniae. Clin Microbiol Infect 20: O831–O839. https://doi.org/10.1111/1469-0691.12677.
23. Bonomo RA. 2017. -Lactamases: a focus on current challenges. Cold Spring Harb Perspect Med 7:a025239. https://doi.org/10.1101/cshperspect.a025239.
24. Nguyen HM, Shier KL, Graber CJ. 2014. Determining a clinical framework for use of cefepime and -lactam/-lactamase inhibitors in the treatment of infections caused by extended-spectrum-lactamase-producing Enterobacteriaceae. J Antimicrob Chemother 69:871–880. https://doi.org/10.1093/jac/dkt450.
25. 2. Ambrose PG, Bhavnani SM, Jones RN. 2003. Pharmacokinetics-pharmacodynamics of cefepime and piperacillin-tazobactam against Escherichia coli and Klebsiella pneumoniae strains producing extended-spectrum-lactamases: report from the ARREST program. Antimicrob Agents Chemother 47:1643–1646. https://doi.org/10.1128/AAC.47.5.1643-1646.2003.
26. Ofer-Friedman H, Shefler C, Sharma S, Tirosh A, Tal-Jasper R, Kandipalli D, Sharma S, Bathina P, Kaplansky T, Maskit M, Azouri T, Lazarovitch T, Zaidenstein R, Kaye KS, Marchaim D. 2015. Carbapenems versus piperacillin-tazobactam for bloodstream infections of nonurinary source caused by extended-spectrum beta-lactamase-producing Enterobacteriaceae. Infect Control Hosp Epidemiol 36:981–985. https://doi.org/10.1017/ice.2015.101.
27. Tamma PD, Han JH, Rock C, Harris AD, Lautenbach E, Hsu AJ, Avdic E, Cosgrove SE; Antibacterial Resistance Leadership Group. 2015. Carbap-enem therapy is associated with improved survival compared with piperacillin-tazobactam for patients with extended-spectrum B-lactamase bacteremia. Clin Infect Dis 60:1319–1325. https://doi.org/10.1093/cid/civ003.
28. Farrell DJ, Flamm RK, Sader HS, Jones RN. 2013. Antimicrobial activity of ceftolozane-tazobactam tested against Enterobacteriaceae and Pseu-domonas aeruginosa with various resistance patterns isolates in U.S. hospitals (2011–2012). Antimicrob Agents Chemother 57:6305–6310. https://doi.org/10.1128/AAC.01802-13.
29. Harris PN, Peleg AY, Iredell J, Ingram PR, Miyakis S, Stewardson AJ, Rogers BA, McBryde ES, Roberts JA, Lipman J, Athan E, Paul SK, Baker P, Harris-Brown T, Paterson DL. 2015. Meropenem versus piperacillin-tazobactam for definitive treatment of bloodstream infections due to ceftriaxone non-susceptible Escherichia coli and Klebsiella spp (the MERINO trial): study protocol for a randomised controlled trial. Trials 16:24. https://doi.org/10.1186/s13063-014-0541-9.
30. Clinical and Laboratory Standards Institute. 2017. Performance standards for antimicrobial susceptibility testing, 27th ed. CLSI supplement M100S. CLSI, Wayne, PA.
31. Huang Y, Carroll KC, Cosgrove SE, Tamma PD. 2014. Determining the optimal ceftriaxone MIC for triggering extended-spectrum-lactamase confirmatory testing. J Clin Microbiol 52:2228–2230. https://doi.org/10.1128/JCM.00716-14.
32. Gavin PJ, Suseno MT, Thomson RB, Jr, Gaydos JM, Pierson CL, Halstead DC, Aslanzadeh J, Brecher S, Rotstein C, Brossette SE, Peterson LR. 2006. Clinical correlation of the CLSI susceptibility breakpoint for piperacillin-tazobactam against extended-spectrum-beta-lactamase-producing Escherichia coli and Klebsiella species. Antimicrob Agents Chemother 50:2244–2247. https://doi.org/10.1128/AAC.00381-05.
33. Retamar P, López-Cerero L, Muniain MA, Pascual A, Rodríguez-Baño J. 2013. Impact of the MIC of piperacillin-tazobactam on the outcome of patients with bacteremia due to extended-spectrum-lactamase-producing Escherichia coli. Antimicrob Agents Chemother 57:3402–3404. https://doi.org/10.1128/AAC.00135-13.